ArticleJACC. Advances2025
The Colorado Heart Failure Acuity Risk Model: A Mortality Model for Waitlisted Cardiac Transplant Patients.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, there is no mathematical model used nationally to determine the medical urgency of patients on the heart transplant waitlist in the United States. While the current organ distribution system accounts for many patient factors, a truly objective model is needed to more reliably stratify patients by their medical acuity. Objectives: The aim of the study was to develop risk scores (Colorado Heart failure Acuity Risk Model [CHARM] score) to predict mortality in adults waitlisted for heart transplant. Methods: Risk scores were based on multivariable logistic regression models with mortality endpoints at 90 days, 180 days, 1 year, and 2 years. The models included serology data and patient history variables from waitlisted patients (N = 4,176) within the Scientific Registry of Transplant Recipients database from January 1, 2017, to September 2, 2023. Results: The CHARM score included serum markers (brain natriuretic peptide, creatinine, sodium, aspartate aminotransferase, albumin, total bilirubin) and clinical variables (history of cardiac surgery, prior transplant, willingness to accept an hepatitis C virus positive heart, use of extracorporeal membrane oxygenation, use of mechanical life support, implantation of a cardiac defibrillator, and ventilator support prior to transplant). Sample holdout-validation for the models yielded average area under the curves of 0.825 (90-day), 0.805 (180-day), 0.779 (1-year), and 0.766 (2-year). Risk indices for all models were 99% correlated with observed mortality rates. Conclusions: The CHARM score provides reliable calibration and prediction, offering an objective system for identifying critically ill patients on the heart transplant waitlist. The CHARM score will be useful in the era of continuous distribution to standardize organ allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.